<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02007486</url>
  </required_header>
  <id_info>
    <org_study_id>MCRDF 2013</org_study_id>
    <nct_id>NCT02007486</nct_id>
  </id_info>
  <brief_title>Pathophysiological Mechanisms of Activity-Related Dyspnea in Heart Failure: A Pilot Study</brief_title>
  <official_title>Pathophysiological Mechanisms of Activity-Related Dyspnea in Heart Failure: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dyspnea (breathlessness) on exertion is the most prevalent and distressing symptom of heart&#xD;
      failure (HF). Nevertheless, the mechanisms of dyspnea in HF remain poorly understood. Thus,&#xD;
      the general aim of this pilot study is to advance our understanding of the mechanisms of&#xD;
      activity-related dyspnea in patients with HF. Studies will be performed in patients with&#xD;
      mild, moderate and severe HF (n=24) as well as in healthy, age- and sex-matched control&#xD;
      subjects (n=8). We will test the hypothesis that the increased prevalence and severity of&#xD;
      activity-related dyspnea in HF reflects the interaction between an exaggerated drive to&#xD;
      breathe and the inability of the respiratory system to meet this increased demand. Detailed&#xD;
      physiological and perceptual responses to bicycle exercise will be examined and compared,&#xD;
      first, between HF patients and healthy control subjects and, second, across patients with&#xD;
      varying degrees of HF severity. The results from this preliminary study will be used to help&#xD;
      design future studies in this patient population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensory intensity (Borg 0-10 scale) ratings of dyspnea at a standardized sub-maximal work rate during exercise</measure>
    <time_frame>Patients will be followed until all study visits are complete, an expected average of 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Esophageal electrode catheter-derived measurements of the diaphragm EMG at a standardized sub-maximal work rate during exercise.</measure>
    <time_frame>Patients will be followed until all study visits are complete, an expected average of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Power output (measured in watts) at the symptom-limited peak of incremental cycle ergometer exercise testing</measure>
    <time_frame>Patients will be followed until all study visits are complete, an expected average of 2 weeks.</time_frame>
    <description>The highest power output (measured in watts) that the study participants are able to sustain for greater than or equal to 30 seconds will be defined as the &quot;symptom-limited peak power output&quot; and used as a secondary outcome measure in this study.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Heart Failure: NYHA functional class I</arm_group_label>
    <description>Ambulatory and clinically-stable patients with New York Heart Association Functional Class I heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of &lt;45%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart Failure: NYHA functional class II</arm_group_label>
    <description>Ambulatory and clinically-stable patients with New York Heart Association Functional Class II heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of &lt;45%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart Failure: NYHA functional class III</arm_group_label>
    <description>Ambulatory and clinically-stable patients with New York Heart Association Functional Class III heart failure and a left ventricular ejection fraction (LVEF) on echocardiography of &lt;45%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control Subjects</arm_group_label>
    <description>Healthy, sedentary, non-smoking, age- and sex-matched control subjects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiopulmonary Exercise Testing</intervention_name>
    <description>Symptom-limited incremental exercise testing (10 watts/min) on an electronically braked cycle ergometer</description>
    <arm_group_label>Healthy Control Subjects</arm_group_label>
    <arm_group_label>Heart Failure: NYHA functional class I</arm_group_label>
    <arm_group_label>Heart Failure: NYHA functional class II</arm_group_label>
    <arm_group_label>Heart Failure: NYHA functional class III</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Ambulatory, male and female heart failure patients (n=24) will be recruited from the Heart&#xD;
        Failure and Heart Transplant Centre of the Royal Victoria Hospital, McGill University&#xD;
        Health Centre. Healthy, sedentary, non-smoking, asymptomatic, control subjects (n=8) will&#xD;
        be recruited through advertisement in the Montr√©al and surrounding area&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Heart Failure Patients:&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  Greater than or equal to 40 years&#xD;
&#xD;
          -  Greater than or equal to 6 month history of Heart Failure due to ischemic or&#xD;
             idiopathic causes&#xD;
&#xD;
          -  New York Heart Association Functional Class I (n=8), II (n=8) and III (n=8)&#xD;
&#xD;
          -  Ambulatory&#xD;
&#xD;
          -  Clinically Stable, as evidenced by no change in medication dosage or frequency of&#xD;
             administration and no exacerbations or hospitalizations due to Heart Failure in the&#xD;
             preceding 3-months&#xD;
&#xD;
          -  Left Ventricular Ejection Fraction on echocardiography of less than or equal to 45%&#xD;
             determined in the preceding 12-months.&#xD;
&#xD;
        Exclusion Criteria for Heart Failure Patients:&#xD;
&#xD;
          -  Chronic obstructive lung disease and/or active disease other than Heart Failure (e.g.,&#xD;
             bronchial asthma; pulmonary arterial hypertension that is not considered secondary to&#xD;
             left heart failure; peripheral artery disease; primary valvular disease; neurological,&#xD;
             cognitive, neuromuscular, endocrine, kidney, metabolic and/or musculoskeletal disease)&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  Intermittent claudication&#xD;
&#xD;
          -  History of dangerous cardiac arrhythmias&#xD;
&#xD;
          -  Myocardial infarction and/or stroke in the preceding 6-months&#xD;
&#xD;
          -  Use of a pacemaker or cardiac resynchronization device&#xD;
&#xD;
          -  Use of domiciliary oxygen and/or exercise-induced arterial oxyhemoglobin desaturation&#xD;
             to &lt;80% on room air&#xD;
&#xD;
          -  Current and/or ex-smoker with a cigarette smoking history of greater than or equal to&#xD;
             10 pack years&#xD;
&#xD;
          -  Body mass index less than 18.5 or greater than or equal to 35.0 kg/m2&#xD;
&#xD;
          -  Use of antidepressant, opioid and/or anti-coagulant drugs in the preceding 4-weeks&#xD;
&#xD;
          -  Evidence of periodic breathing (or oscillatory ventilation) on initial exercise&#xD;
             testing&#xD;
&#xD;
          -  Evidence of significant sleep-disordered breathing (i.e., apnea-hypopnea index &gt;15&#xD;
             events/hour of sleep) based on overnight polysomnography performed within preceding&#xD;
             12-months.&#xD;
&#xD;
        Inclusion Criteria for Healthy Control Subjects:&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  Greater than or equal to 40 years&#xD;
&#xD;
          -  Non-smoker&#xD;
&#xD;
        Exclusion Criteria for Healthy Control Subjects:&#xD;
&#xD;
          -  History of cardiovascular, cerebrovascular, pulmonary, musculoskeletal, neuromuscular,&#xD;
             renal, endocrine, metabolic, neurologic and/or cognitive disease/dysfunction.&#xD;
&#xD;
          -  Evidence of exercise-induced myocardial ischemia on ECG&#xD;
&#xD;
          -  Evidence of exercise-induced oxyhemoglobin desaturation to &lt;80% on room air&#xD;
&#xD;
          -  Taking regular medication(s)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Jensen, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McConnell Centre for Innovative Medicine, Research Institute of the McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.mcgill.ca/cerpl</url>
    <description>Clinical Exercise &amp; Respiratory Physiology Laboratory (CERPL) of McGill University</description>
  </link>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>November 28, 2013</study_first_submitted>
  <study_first_submitted_qc>December 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2013</study_first_posted>
  <last_update_submitted>February 10, 2017</last_update_submitted>
  <last_update_submitted_qc>February 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University</investigator_affiliation>
    <investigator_full_name>Dennis Jensen, Ph.D.</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Exercise</keyword>
  <keyword>Dyspnea</keyword>
  <keyword>Diaphragm electromyogram</keyword>
  <keyword>Respiratory mechanics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

